Rebekah Milliron
Family · Lincolnton, NCNPI 1316489081
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 244 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 12.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,780, more than ten times the $14 reported in 2023. Among family clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 244 payments — averaging $21.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$654
- Novo Nordisk$448
- Amgen$410
- Corcept Therapeutics$312
- Antares Pharma, Inc.$292
- Dexcom, Inc.$288
- plus $3K from 31 others
What the payments were for
- Food & beverage$4,99697%
- Education$1653%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 45 | $654 |
| Novo Nordisk | 27 | $448 |
| Amgen | 20 | $410 |
| Corcept Therapeutics | 10 | $312 |
| Antares Pharma, Inc. | 12 | $292 |
| Dexcom, Inc. | 14 | $288 |
| Abbott | 12 | $237 |
| Sanofi-aventis U.S. LLC | 10 | $219 |
| Sequel Med Tech, LLC | 3 | $186 |
| Medtronic | 2 | $167 |
| Radius Health, Inc. | 7 | $162 |
| Ascendis Pharma Endocrinology Inc | 6 | $158 |
| Bayer | 7 | $148 |
| Mannkind Corporation | 8 | $137 |
| Xeris Pharmaceuticals, Inc. | 2 | $136 |
| Tandem Diabetes Care, Inc. | 2 | $133 |
| AbbVie | 8 | $132 |
| Amneal Pharmaceuticals LLC | 8 | $121 |
| BETA Bionics, Inc. | 4 | $100 |
| Amphastar Pharmaceuticals, Inc. | 6 | $93 |
| Boehringer Ingelheim | 4 | $80 |
| Recordati_rare_diseases_inc. | 3 | $57 |
| Tolmar, Inc. | 2 | $53 |
| Aimmune Therapeutics, Inc. | 2 | $51 |
| Chiesi USA, Inc. | 2 | $51 |
| IBSA Pharma Inc. | 2 | $42 |
| Novartis | 3 | $42 |
| AstraZeneca | 2 | $40 |
| Cequr Corporation | 2 | $40 |
| Vivus LLC | 2 | $36 |
| Kyowa Kirin, Inc. | 1 | $26 |
| Insulet Corporation | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Almatica Pharma LLC | 1 | $19 |
| Rhythm Pharmaceuticals, Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| VBI Vaccine (delaware) Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVENITY$150
- MINIMED 780G$150
- TWIIST$142
- Korlym$124
- RECORLEV$121
- MOUNJARO$118
- t:slim X2 Insulin Pump with Control-IQ$113
How this compares
$5,161 in reported general payments places this provider in the 90th percentile of 4,522 family providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 96 | $107,294 |
| MounjaroTirzepatide | 61 | $79,635 |
| JardianceEmpagliflozin | 26 | $29,484 |
| EliquisApixaban | 23 | $17,889 |
| JanuviaSitagliptin Phosphate | 13 | $12,620 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $6,951 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $6,490 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $3,464 |
| SynthroidLevothyroxine Sodium | 15 | $1,635 |
| Omeprazole | 61 | $895 |
| Levothyroxine Sodium | 71 | $602 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $593 |
| Gabapentin | 35 | $388 |
| Losartan Potassium | 43 | $360 |
| Atorvastatin Calcium | 49 | $334 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $448 | $107,29496 claims |
| Lilly USA, LLCMounjaro | $654 | $79,63561 claims |
| Boehringer IngelheimJardiance | $80 | $29,48426 claims |
| AbbVieSynthroid | $132 | $1,63515 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $121 | $60271 claims |
| Almatica Pharma LLCSertraline Hcl | $19 | $28929 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,522 family providers in North Carolina.
Other family in Lincolnton
- Matthew SeagleLincolnton$20K
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.